HDC followed by autologous stem-cell support is a well-tolerated therapeutic approach for patients with poor-prognosis ovarian carcinoma. In this report, the 59.9% survival of 53 patients at 5 years must be compared to the 20% to 30% 5-year survival observed after conventional therapy. These results should be confirmed by an ongoing prospective randomized trial.

No abstract

Summary:graft contains monocytes which produce several cytokines including G-CSF. 6,7 Randomized studies have demonstrated that r-Hu G-CSF In this placebo-controlled randomized trial we evaluated the hematological and clinical effects of r-Hu GM-(recombinant human granulocyte colony-stimulating factor) or r-Hu GM-CSF (recombinant human granulocyte-macro-CSF after high-dose chemotherapy (HDC) followed by GM-CSF-mobilized PBPC transplantation. Fifty phage colony-stimulating factor) accelerate granulocyte recovery after bone marrow transplantation. [8][9][10][11][12] On the patients with poor prognosis malignancies were randomized in a double-blind study to receive either GMother hand, there are few and controversial reports concerning the efficiency of colony-stimulating factors (CSFs) on CSF or placebo after HDC followed by PBPC rescue. For all patients, PBPCs were recruited using a combithe hematological recovery and on the frequency of infectious complications after PBPC transplantation. [13][14][15][16][17][18] At the nation of VP-16 (300 mg/m 2 on days 1 and 2), cytoxan (3 g/m 2 on days 3 and 4) and GM-CSF (5 g/kg from present time, no randomized studies are available regarding the effect of GM-CSF after PBPC transplantation and retroday 5). No differences were demonstrated between the two groups in median time to neutrophil or platelet spective studies are few and not conclusive. 19In this unicenter placebo-controlled randomized trial we recoveries. There was no significant difference between the GM-CSF group and the placebo group in the investigate the effect of r-Hu GM-CSF after GM-CSF-mobilized PBPC transplant. We report neutrophil and platelet median duration of post-transplant hospitalization, in the number of days of antibiotic treatment, in the numrecoveries and related clinical parameters such as the number of febrile days, the rate of infections, the duration of ber of infections and in red blood cell or platelet transfusion requirements. There was a significant difference parenteral antibiotherapy and the time to discharge from hospital after PBPC transplantation. with an advantage for the placebo group in the mean duration of febrile days (P = 0.01). We conclude that the administration of GM-CSF in patients transplanted Patients and methods with GM-CSF-mobilized PBPC is not associated with a clinical benefit in term of tempo of engraftment, numInclusion criteria bers of documented infections, transfusion requirements and mucositis grading.

Total parenteral nutrition enriched with arginine and glutamate promotes a better nitrogen balance, limits protein myofibrillar catabolism, and generates glutamine, with arginine (not glutamate) probably being the main contributor to the glutamine-generating effect of the solution through the formation of ornithine.